Browsing Institutt for klinisk medisin by Author "Yabe, Daisuke"
Now showing items 1-2 of 2
-
Karasik, Avraham; Lanzinger, Stefanie; Chia-Hui Tan, Elise; Yabe, Daisuke; Kim, Dae Jung; Sheu, Wayne H-H; Melzer-Cohen, Cheli; Holl, Reinhard W.; Ha, Kyoung Hwa; Khunti, Kamlesh; Zaccardi, Francesco; Subramanian, Anuradhaa; Nirantharakumar, Krishnarajah; Nyström, Thomas; Niskanen, Leo; Linnemann Jensen, Majken; Hoti, Fabian; Klement, Riho; Déruaz-Luyet, Anouk; Kyaw, Moe H.; Koeneman, Lisette; Vistisen, Dorte; Carstensen, Bendix; Halvorsen, Sigrun; Langslet, Gisle; Fazeli Farsani, Soulmaz; Patorno, Elisabetta; Núñez, Júlio (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2023)Background Continued expansion of indications for sodium-glucose cotransporter-2 inhibitors increases importance of evaluating cardiovascular and kidney efficacy and safety of empagliflozin in patients with type 2 ...
-
Vistisen, Dorte; Carstensen, Bendix; Elisabetta, Patorno; Lanzinger, Stefanie; Tan, Elise C.; Yabe, Daisuke; Kim, Dae J.; Sheu, Wayne H.; Melzer-Cohen, Cheli; Holl, Reinhard W.; Núñez, Júlio; Ha, Kyoung H.; Halvorsen, Sigrun; Langslet, Gisle; Karasik, Avraham; Nyström, Thomas; Niskanen, Leo; Guleria, Sonia; Klement, Riho; Carrasco, Marc; Foersch, Johannes; Shay, Christina; Koeneman, Lisette; Hoti, Fabian; Farsani, Soulmaz F.; Khunti, Kamlesh; Zaccardi, Francesco; Subramanian, Anuradhaa; Nirantharakumar, Krishnarajah (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2023)Background Studies that have reported lower risk for cardiovascular outcomes in users of Sodium–Glucose Cotransporter-2 Inhibitors (SGLT-2i) are limited by residual cofounding and lack of information on ...